Peptide Lifestyle 360
Understand the research. Explore the possibilities. A cited peptide research library with approval status first, guided calculators with optional verified label presets you confirm, a research studio for comparing evidence, and a dated research feed. No doses. Not medical advice.
Start here
Read any entry in sixty seconds
- Read the status line — Every entry opens with whether a regulator approved it, for what, and where.
- Check the evidence label — Human trials, animal work or reports: the label says which, before anything else.
- Learn label words — Mass, volume and concentration, explained with pictures before any arithmetic.
Common questions
- Is Ozempic the same thing as Wegovy?
- What does GLP-1, GIP and glucagon actually mean on the label?
- My vial says semaglutide but it is not a pen. Is that the same drug?
- Why can't I just start at the amount that works?
- My doctor said go up in four weeks. What if I do not want to?
- Is the top of the schedule the goal?
Changes to this site
- New guide: how long a vial lasts after opening (2026-11-11) — Label rules by product, including EGRIFTA WR (7 days at room temperature) and SV (use immediately). No universal 28-day rule.
- Evidence ladder audit (2026-11-11) — The human-trial step now lights only from classified human sources. Trenbolone, boldenone, stanozolol and testosterone entries were corrected.
- Klotho entry corrected (2026-11-11) — The published topical pilot is now kept apart from the systemic registry trials, with its limits stated.
What is this site?
A free, cited reference. It explains what is known about peptides and related compounds, where each one stands with regulators, and what the evidence does not show.
Does it recommend anything?
No. There are no doses, schedules or product picks, and nothing is sold here. Questions about your own care belong with a prescriber or pharmacist.
What does the regulatory status mean?
Whether a regulator has approved a product containing the compound, for what use and where. Approval in one country, or for one product, does not cover others.
Survodutide cardiovascular trial meets its primary safety endpoint (2026-11-09)
In a large trial of adults with raised heart risk, the sponsor reports survodutide met its heart-safety goal against placebo. That is a safety result; it does not show the drug prevents heart attacks or strokes. Survodutide is still investigational. Primary source
HHS publishes a draft peptide compounding enforcement policy (2026-10-30)
HHS published a draft describing when it may not act against certain compounded peptides. A draft is not a final rule and not an approval, and compounded products are not FDA-approved. Primary source
Lilly reports retatrutide results in a type 2 diabetes comparison trial (2026-10-28)
In adults with type 2 diabetes not controlled on their current treatment, the company reports retatrutide lowered A1C and weight more than injectable semaglutide (Ozempic). These are the sponsor's first results, in one population; retatrutide is not approved. Primary source
Educational use only, never medical advice. No doses.